Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size

Endocrine Journal

Yuuki Takamura²  Akihiro Miya²  Minoru Kihara²  Yasuhiro Ito²  Kaoru Kobayashi²  Mitsuhiro Fukushima¹  Akira Miyauchi² 

[1] Department of Surgery, Kuma Hospital, Kobe 650-0011, Japan

关键词: Papillary thyroid carcinoma;    Prognosis;    Tumor size;    Extrathyroid extension;    Lymph node metastasis;   

DOI  :  10.1507/endocrj.EJ12-0013

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(20)Cited-By(11)In papillary thyroid carcinoma (PTC), extrathyroid extension (Ex) and clinical lymph node metastasis (N) significantly affect the prognosis.We investigated the prognosis of patients with PTC 1 cm or less (1,220 patients), 1.1-2 cm (2,101 patients), 2.1-3 cm (1,249 patients), 3.1-4 cm (645 patients), and larger than 4 cm (563 patients). We classified N factor into three categories: N0, no clinical node metastasis: N1, clinical node metastasis smaller than 3 cm and without extranodal tumor extension requiring at least partial excision of adjacent organs for node dissection: and N2, clinical node metastasis 3 cm or larger or showing extranodal tumor extension. N2 markedly affected lymph node and distant recurrence-free survivals and cause-specific survival, regardless of the tumor size.N1 also adversely affected lymph node and distant recurrence-free survival but not cause-specific survival.Ex did not affect patients’ prognosis with PTC 1 cm or less.It became a prognostic factor with PTC larger than 1 cm, and worsened lymph node and distant recurrence-free survival not only for N0 but also for N1 PTC larger than 3 cm and larger than 2 cm, respectively. However, its influence is limited for N2 PTC patients.Furthermore, Ex worsened the CSS with PTC larger than 2 cm in combination with N2.We have to note that the prognostic significance for lymph node and distant recurrence-free and cause-specific survival of Ex and N varies according to the tumor size in order to accurately predict the clinical outcomes and establish therapeutic strategies for PTC patients.

【 授权许可】

Unknown